trending Market Intelligence /marketintelligence/en/news-insights/trending/pyhl6862skmsbsovpq2bxa2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Gilead Sciences licenses California-based company's drug discovery technology

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Gilead Sciences licenses California-based company's drug discovery technology

Gilead Sciences Inc. said it entered a license agreement with San Francisco-based Trianni Inc. to use its drug discovery platform.

The financial details of the agreement were not disclosed in a Sept. 4 news release.

Trianni's transgenic human monoclonal antibody discovery platform uses genetically engineered mice to generate antibodies that can be effective in humans.